Washington Trust’s TG Therapeutics TGTX Stock Holding History

Washington Trust’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-342	Closed	-$4K	–	746
2018 Q2	$4K	Buy	+342	New	+$4.7K	﹤0.01%	778

Other funds holding TGTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Washington Trust's TGTX Position: Q3 2018 in Review

Washington Trust sold out of TG Therapeutics (TGTX) in Q3 2018, closing a stake of 342 shares — an estimated $4K sold.

Washington Trust first reported a position in TGTX in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 127 funds tracked by Wall St. Rank hold TGTX as of Q3 2018.

Washington Trust reported no remaining TG Therapeutics position as of Q3 2018 after selling out during the quarter.
Washington Trust sold 342 TG Therapeutics shares in Q3 2018, an estimated $4K.
Washington Trust first reported a position in TG Therapeutics in Q2 2018 and held it in 1 quarter.
Washington Trust's TG Therapeutics position peaked at $4K in Q2 2018.
127 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2018.

Based on Washington Trust's 13F filing for Q3 2018, filed 13 Nov 2018.